Biggest News Aggregation in the World
📰 Global Phase News

Global Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Global Phase. Real-time updates on events, politics, business and more.

Guardant Health, Inc.: Guardant Health Receives EU IVDR Certification for Guardant360 CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

Blood-based test for comprehensive genomic profiling of solid cancers meets requirements under stricter EU In Vitro Diagnostic Regulation IVDR certification from TÜV SÜD enables broader adoption
Emilia Romagna Michael Weist Nicola Normanno Zarak Khurshid Dino Amadori Helmy Eltoukhy

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024

– Data from pivotal Phase III STARS study in short bowel syndrome with intestinal failure accepted as late-breaker oral presentation on May 21 at 10:30 am ET – – Findings from the STARS...
United States Michael Shetzline Ironwood Pharmaceuticals Nasdaq Exchange Commission A National Survey Analysis Ironwood Pharmaceuticals

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week 2024

01.05.2024 - Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a ... Seite 1
Michael Shetzline Drug Administration Center Trial Ironwood Pharmaceuticals Apraglutide Once Weekly Short Bowel Syndrome

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab TAK079 a Potential BestinClass AntiCD38 Monoclonal Antibody for Primary Immune Thrombocytopenia

TakedaTSE4502NYSETAK today announced positive topline results from a Phase 2 randomized doubleblind placebocontrolled study evaluating the safety tolerability and efficacy of mezagitamab TAK079 in patients with persistent or chronic primary immune thrombocytopenia ITP.
United States Chinwe Ukomadu Yuko Yoneyama Rodeghierof International Journal Of Hematology Takeda Pharmaceutical Company Limited Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science